Yinuo Pang

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

Geert D’Haens, Remo Panaccione, Filip Baert et al. · The Lancet · 2022 · 387 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +9

Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Marc Ferrante, Remo Panaccione, Filip Baert et al. · The Lancet · 2022 · 316 citations · Full text

Pharmacy, Clinical Sciences, Pharmacotherapy +11

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study

Marc Ferrante, Brian G. Feagan, Julián Panés et al. · Journal of Crohn s and Colitis · 2021 · 70 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of <scp>ABBV</scp>‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with <scp>Moderate‐to‐Severe</scp> Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, <scp>Double‐Blind</scp>, <scp>Active‐Controlled Proof‐of‐Concept</scp> Phase <scp>IIa</scp> Trial

Frank Buttgereit, Jacob Aelion, Bernadette Rojkovich et al. · Arthritis & Rheumatology · 2022 · 53 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up

Kim Papp, Andrew Blauvelt, L. Puig et al. · Journal of the American Academy of Dermatology · 2023 · 46 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +15